Browsing by Author "Ünal, E."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
Item Open Access Immunodeficiency associated with a novel functionally defective variant of SLC19A1 benefits from folinic acid treatment(Springer Nature, 2022-12-15) Gök, V.; Erdem, Ş.; Haliloğlu, Y.; Bişgin, A.; Belkaya, Serkan; Başaran, K. E.; Canatan, M. F.; Özcan, A.; Yılmaz, E.; Acıpayam, C.; Karakükcü, M.; Canatan, H.; Per, H.; Patıroğlu, T.; Eken, A.; Ünal, E.Insufficient dietary folate intake, hereditary malabsorption, or defects in folate transport may lead to combined immunodeficiency (CID). Although loss of function mutations in the major intestinal folate transporter PCFT/SLC46A1 was shown to be associated with CID, the evidence for pathogenic variants of RFC/SLC19A1 resulting in immunodeficiency was lacking. We report two cousins carrying a homozygous pathogenic variant c.1042 G > A, resulting in p.G348R substitution who showed symptoms of immunodeficiency associated with defects of folate transport. SLC19A1 expression by peripheral blood mononuclear cells (PBMC) was quantified by real-time qPCR and immunostaining. T cell proliferation, methotrexate resistance, NK cell cytotoxicity, Treg cells and cytokine production by T cells were examined by flow cytometric assays. Patients were treated with and benefited from folinic acid. Studies revealed normal NK cell cytotoxicity, Treg cell counts, and naive-memory T cell percentages. Although SLC19A1 mRNA and protein expression were unaltered, remarkably, mitogen induced-T cell proliferation was significantly reduced at suboptimal folic acid and supraoptimal folinic acid concentrations. In addition, patients’ PBMCs were resistant to methotrexate-induced apoptosis supporting a functionally defective SLC19A1. This study presents the second pathogenic SLC19A1 variant in the literature, providing the first experimental evidence that functionally defective variants of SLC19A1 may present with symptoms of immunodeficiency.Item Open Access Implantable microelectromechanical sensors for diagnostic monitoring and post-surgical prediction of bone fracture healing(John Wiley and Sons Inc., 2015) McGilvray, K. C.; Ünal, E.; Troyer, K. L.; Santoni, B. G.; Palmer, R. H.; Easley, J. T.; Demir, Hilmi Volkan; Puttlitz, C. M.The relationship between modern clinical diagnostic data, such as from radiographs or computed tomography, and the temporal biomechanical integrity of bone fracture healing has not been well-established. A diagnostic tool that could quantitatively describe the biomechanical stability of the fracture site in order to predict the course of healing would represent a paradigm shift in the way fracture healing is evaluated. This paper describes the development and evaluation of a wireless, biocompatible, implantable, microelectromechanical system (bioMEMS) sensor, and its implementation in a large animal (ovine) model, that utilized both normal and delayed healing variants. The in vivo data indicated that the bioMEMS sensor was capable of detecting statistically significant differences (p-value <0.04) between the two fracture healing groups as early as 21 days post-fracture. In addition, post-sacrifice micro-computed tomography, and histology data demonstrated that the two model variants represented significantly different fracture healing outcomes, providing explicit supporting evidence that the sensor has the ability to predict differential healing cascades. These data verify that the bioMEMS sensor can be used as a diagnostic tool for detecting the in vivo course of fracture healing in the acute post-treatment period. © 2015 Orthopaedic Research Society. Published by Wiley Periodicals, Inc.